Every stage of biopharma drug development depends on what happens in the laboratory. Consequently, any one of these stages—which include target identification, lead optimization, candidate ...

Using a new data set of key development milestones for drugs approved between 2006 and 2020, ... Our analysis suggests that the BTD program lowers late-stage clinical development time by 30 percent.

Drug development is a long and costly process. On the other hand, while AI platforms may rapidly identify compounds that work on cells in a Petri dish or in animal models, the success of these ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares ...

Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced the appointments of multiple se ...

The current drug development process operates like an assembly line, relying on a checkbox approach with extensive testing at each step of the process.While AI may be able to reduce the time and cost ...

These trials had a total patient enrollment of 25,002 patient-participants in 608 specific treatment cohorts testing 332 drugs. The median enrollment per trial was 62 patients. Most patients (73% ...

Behind every drug in your pharmacy are many, many more that failed. nortonrsx/iStock via Getty Images Plus We have been following the use of AI in drug development in our work as a pharmaceutical ...

The decision to advance prasinezumab to late-stage development was based on data from the phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and phase II PASADENA studies.